| abstract |
The present invention relates to the use of secretory leucocyte protease inhibitor (SLPI), or a non-pathogenic microorganism capable of forming SLPI and containing a nucleic acid coding for SLPI, for the treatment of chronic inflammatory intestinal diseases of humans and animals, pharmaceutical compositions for oral or rectal administration which contain the effective material SLPI or SLPI-expressing microorganisms, and methods for the production of these pharmaceutical compositions. |